Gargoyle Investment Advisor L.L.C. purchased a new stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 3,685 shares of the specialty pharmaceutical company’s stock, valued at approximately $291,000.

Other large investors have also modified their holdings of the company. Louisiana State Employees Retirement System raised its stake in shares of Eagle Pharmaceuticals by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 3,300 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System raised its position in Eagle Pharmaceuticals by 2.4% in the first quarter. Arizona State Retirement System now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $348,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its position in Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 120 shares in the last quarter. Texas Permanent School Fund raised its position in Eagle Pharmaceuticals by 2.2% in the first quarter. Texas Permanent School Fund now owns 5,867 shares of the specialty pharmaceutical company’s stock valued at $487,000 after buying an additional 125 shares in the last quarter. Finally, Mason Street Advisors LLC raised its position in Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock valued at $157,000 after buying an additional 175 shares in the last quarter.

Eagle Pharmaceuticals, Inc. (EGRX) opened at 54.10 on Wednesday. Eagle Pharmaceuticals, Inc. has a 1-year low of $45.05 and a 1-year high of $97.15. The stock’s 50 day moving average is $65.84 and its 200 day moving average is $76.01. The firm has a market capitalization of $820.64 million, a price-to-earnings ratio of 9.08 and a beta of 1.31.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share for the quarter, missing analysts’ consensus estimates of $0.51 by $0.18. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The firm had revenue of $50.10 million for the quarter, compared to the consensus estimate of $52.52 million. During the same period in the previous year, the business earned $0.80 earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. Analysts predict that Eagle Pharmaceuticals, Inc. will post $3.61 EPS for the current fiscal year.

Eagle Pharmaceuticals announced that its board has initiated a share repurchase program on Wednesday, August 9th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the specialty pharmaceutical company to reacquire up to 13.3% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: “Gargoyle Investment Advisor L.L.C. Takes Position in Eagle Pharmaceuticals, Inc. (EGRX)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/gargoyle-investment-advisor-l-l-c-takes-position-in-eagle-pharmaceuticals-inc-egrx/1494394.html.

Several research analysts have recently weighed in on EGRX shares. BidaskClub lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Piper Jaffray Companies set a $118.00 price objective on shares of Eagle Pharmaceuticals and gave the stock an “overweight” rating in a research note on Tuesday, May 9th. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 16th. Royal Bank Of Canada boosted their price objective on shares of Eagle Pharmaceuticals from $86.00 to $94.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 9th. Finally, Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Three analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $75.40.

In related news, CFO Pete A. Meyers acquired 350 shares of the firm’s stock in a transaction that occurred on Monday, June 12th. The stock was acquired at an average price of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the acquisition, the chief financial officer now owns 350 shares of the company’s stock, valued at approximately $25,021.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Douglas L. Braunstein acquired 20,400 shares of the firm’s stock in a transaction that occurred on Wednesday, August 9th. The shares were bought at an average price of $49.07 per share, with a total value of $1,001,028.00. The disclosure for this purchase can be found here. Insiders have purchased 21,005 shares of company stock valued at $1,046,370 in the last 90 days. 19.50% of the stock is currently owned by corporate insiders.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.